19/10/2022 - Press release
A multicentre study involving hospitals in Spain and Portugal, led by Hospital del Mar, shows that these patients already receive enough radiation to treat the disease when the breast affected by the tumour is irradiated directly. The study monitored more than 400 women. The results indicate that the five-year survival rate and relapses are practically identical between those who underwent specific treatment targeting the nodes located in the armpits and those who only received breast radiation. The findings of the OPTIMAL study have been published in the journal Radiation Oncology and can now be applied to clinical practice. Thanks to this fact, patients will need less radiotherapy and will suffer fewer treatment-related side effects.
17/10/2022 - Institutional news
It will analyse the role the circadian rhythm alteration of intestinal microbiota plays in the development of Alzheimer's disease. The project is one of the sixty selected in the ninth call for applications for these grants, which reward highly innovative projects in nine areas of scientific knowledge and culture. The project by IMIM-Hospital del Mar researcher Patrick-Simon Welz, 'Losing the rhythm: host-microbiota circadian communication in Alzheimer's disease', is one of the 60 projects selected in the ninth edition of the Leonardo grants, awarded by the BBVA Foundation. These grants support highly innovative proposals in various scientific and cultural fields. This year, 884 applications were submitted and evaluated by 85 independent experts divided into nine panels.
17/10/2022 - Institutional news
The Section Chief of the Gastrointestinal Surgery Department at Hospital del Mar and researcher at the Hospital del Mar Medical Research Institute became a corresponding member of the RAMC, in a ceremony held on 4 October at the institution's headquarters. Dr. Manuel Pera has been a corresponding member of the Royal Academy of Medicine of Catalonia since 4 October. The appointment was made in a ceremony held at the institution's headquarters, in which the Section Chief of the Surgery Department at Hospital del Mar and coordinator of the Gastroesophageal Carcinogenesis research group at the Hospital del Mar Medical Research Institute (IMIM), gave the speech, 'Improving the quality of care in digestive cancer surgery: the experience of the Spanish EURECCA Oesophagogastric Cancer Registry'. The presentation of the new member was led by Dr. Lluís Grande i Posa, full member of the RAMC and Emeritus Chief of Surgery at Hospital del Mar.
05/10/2022 - Press release
A study led by researchers at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) has determined the role that fibroblasts, the cells that contribute to tissue formation, play in a tumour's ability to generate resistance to the most common biological treatment for HER2. The paper, published in the journal Nature Communications, demonstrates the ability of a new therapy, currently undergoing clinical trials, to promote a potent immune response by binding to the fibroblasts, enabling it to overcome resistance to anti-HER2 therapy in tumours with this cancer cell protection mechanism. To demonstrate this, the researchers created a 3D tumour model in which they were able to check the relationships between all the factors involved.
23/08/2022 - General information
A team from Hospital del Mar and the Hospital del Mar Medical Research Institute has validated the technique involving breast biopsy guided by contrast mammography to visualise suspicious lesions that cannot be observed via ultrasound or mammography. After analysing data from tests performed on 64 women, they have been able to verify that this technique offers the same or better results than the other diagnostic tool used in these cases, magnetic resonance imaging (MRI). The results have been published in the journal European Radiology. In the cases studied, contrast mammography-guided breast biopsy was successful in 95.4% of cases. In only three tests was the visibility of the findings not as expected. In comparison, MRI has a success rate of between 87% and 98%.
Més informació "Usefulness of breast biopsy guided by contrast-enhanced mammography is validated"
12/07/2022 - General information
This is one of the fifteen biomedical projects selected in the CaixaResearch Validate call. In this case, the study led by the researcher from the Hospital del Mar Medical Research Institute seeks effective immunotherapy treatment for breast tumours. The "la Caixa" Foundation is supporting 15 leading biomedical research projects in Spain and Portugal in the CaixaResearch Validate 2022 call. These are early-stage projects that the organisation wants to support to accelerate their arrival on the market, thereby helping them reach patients who may need them. Among those selected is a project led by Dr. Toni Celià-Terrassa, who heads up the Cancer Stem Cells and Metastasis Dynamics laboratory at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar).
17/06/2022 - Institutional news
The Friends of the Hospital del Mar Foundation and APRO, the Association for Oncological Research, have awarded Dr. Edurne Arriola more than 8,000 euros to boost immunotherapy and lung cancer research being carried out at Hospital del Mar and the Hospital del Mar Medical Research Institute. Lung cancer research at Hospital del Mar and the Hospital del Mar Medical Research Institute has received a new boost thanks to the Friends of the Hospital del Mar Foundation and APRO, the Association for Oncological Research. The two organisations have managed to raise 8,000 euros, which will be used to support the work of researchers in this field.
30/05/2022 - Press release
A group of genes has been identified in cancerous cells that survive chemotherapy treatment. The activity of these genes leads to treatment resistance and increased capacity for metastasis. This breakthrough opens the door to studying targeted treatments using drug inhibitors of these genes combined with chemotherapy, potentially providing alternatives for patients with a worse prognosis in this type of tumor, accounting for 30% of cases. The research, led by scientists from the Hospital del Mar Medical Research Institute, highlights that this type of tumor cell reverts to an embryonic state. Identifying the factor that triggers this change could aid in designing new treatments for high-risk patients.
31/03/2022 - General information
The project "Tumour microenvironment-derived factors in localised colon cancer: clinical impact and therapeutic implications' (TuMiCC)"aimed at demonstrating the value of the tumour microenvironment in predicting relapse in patients with localised colon cancer treated with adjuvant therapy, has reached the 16-month development milestone, with patient recruitment and interesting advances in the molecular characterisation of this type of tumour and its environment.
17/03/2022 - Press release
Researchers at the Hospital del Mar Medical Research Institute and Hospital del Mar have transformed immunotherapy-resistant tumours into tumours that respond to this treatment, achieving cures in animal models through an innovative therapeutic strategy in triple-negative breast cancer, the most aggressive subtype. Researchers have discovered the essential role of a new factor, LCOR, in enabling cancer cells to present tumour antigens on their surfaces. These antigens allow the immune system to recognise the tumour, an essential step if immunotherapy treatment is to succeed. On the other hand, they have shown that cancer stem cells have very low levels of LCOR, making them invisible to the immune system and therefore resistant to treatment. The work that has just been published used an innovative experimental messenger RNA system, similar to the technology used for COVID-19 vaccines, to produce LCOR in tumour cells. In this way, the resistant tumour cells of triple-negative cancer become visible and sensitive to the immune system. This approach is also being investigated in other breast cancer subtypes
Més informació "Radical increase in the effectiveness of breast cancer immunotherapy"
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
